Blood test may predict prostate cancer drug response, avoiding painful biopsies
NCT ID NCT01961843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test could predict how prostate cancer responds to the drug abiraterone. Instead of taking a tissue sample (biopsy), researchers measured tumor cells circulating in the blood of 40 men with advanced prostate cancer. The goal was to see if changes in these cells could help doctors know if the treatment is working, without needing invasive procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?